StocksA › AVXL

Anavex Life Sciences Corp. (AVXL) — Earnings Call X-Ray

Our AI read all 30 of AVXL's earnings calls (2018–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2025 · sign up to see
Previous Call Grade
F
Q1 2025
Expected Move
🔒
next 45 days · members
Calls Analyzed
30
2018–2025
Avg Candor
5.3/9
evasion 4/9
Promotional ToneCritic AmmunitionReads RehearsedQuestion Left Hanging

Call-by-call analysis

🔒 Q2 2025 earnings call 2025-05-13 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2025 call grade is ready
The full 37-point AI read of AVXL's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

F Q1 2025 earnings call 2025-02-12 move ±14.5%

Management gave no formal guidance. The delivery was promotional in tone.

1 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsed
Candor 4/9
Specificity 6/9
Evasion 4/9
Confidence 8/9
Uncertainty 3/9
Promotion 8/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q4 2024 earnings call 2024-12-23 move ±19.4%

Management gave no formal guidance. The delivery was promotional in tone.

Margins: stable 1 analysts · 2 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 5/9
Specificity 6/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 7/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q2 2024 earnings call 2024-08-06 move ±22.3%

Management gave no formal guidance.

Headcount: growing 2 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging
Candor 5/9
Specificity 6/9
Evasion 4/9
Confidence 7/9
Uncertainty 3/9
Promotion 6/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

F Q2 2024 earnings call 2024-05-09 move ±11.2%

Management gave no formal guidance against contracting margins. The delivery was promotional in tone.

Margins: contractingHeadcount: growing 3 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 5/9
Specificity 6/9
Evasion 5/9
Confidence 7/9
Uncertainty 4/9
Promotion 7/9
Stress 4/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q1 2024 earnings call 2024-02-07 move ±13%

Management gave no formal guidance against contracting margins. The delivery was frequently evasive, promotional in tone.

Margins: contractingCapex: flat 2 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsed
Candor 4/9
Specificity 4/9
Evasion 6/9
Confidence 7/9
Uncertainty 5/9
Promotion 7/9
Stress 3/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q4 2023 earnings call 2023-11-27 move ±18.4%

Management gave no formal guidance.

2 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsed
Candor 5/9
Specificity 6/9
Evasion 4/9
Confidence 7/9
Uncertainty 3/9
Promotion 6/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q3 2023 earnings call 2023-08-08 move ±23.1%

Management gave no formal guidance against contracting margins. The delivery was promotional in tone.

Margins: contractingHeadcount: growingCapex: increasing 1 analysts · 4 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 5/9
Specificity 6/9
Evasion 4/9
Confidence 8/9
Uncertainty 4/9
Promotion 7/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q2 2023 2023-05-09 F maintainedunclearunclear 5/9 3/9
Q1 2023 2023-02-07 F maintainedunclearcontracting 5/9 5/9
Q4 2022 2022-11-28 F maintainedunclearcontracting 4/9 7/9
Q3 2022 2022-08-09 D maintainedunclearcontracting 5/9 3/9
Q2 2022 2022-05-10 D maintainedunclearcontracting 6/9 4/9
Q1 2022 2022-02-09 F noneunclearunclear 5/9 4/9
Q4 2021 2021-11-24 F noneunclearunclear 6/9 5/9
Q3 2021 2021-08-12 F noneunclearunclear 6/9 5/9
Q2 2021 2021-05-13 F noneunclearunclear 5/9 5/9
Q1 2021 2021-02-12 D maintainedacceleratingunclear 6/9 3/9
Q4 2020 2020-12-28 D noneunclearcontracting 6/9 4/9
Q3 2020 2020-08-09 D noneunclearcontracting 6/9 4/9
Q2 2020 2020-05-07 F noneunclearstable 5/9 4/9
Q1 2020 2020-02-06 C+ nonestableunclear 6/9 2/9
Q4 2019 2019-12-16 F noneunclearcontracting 5/9 4/9
Q3 2019 2019-08-07 D noneunclearcontracting 6/9 4/9
Q2 2019 2019-05-09 D noneunclearcontracting 6/9 3/9
Q1 2019 2019-02-07 D noneunclearcontracting 6/9 3/9
Q4 2018 2018-12-12 D maintainedstablecontracting 6/9 4/9
Q3 2018 2018-08-09 C noneunclearcontracting 6/9 2/9
Q1 2018 2018-05-11 F noneunclearcontracting 6/9 3/9
Q1 2018 2018-02-07 F noneunclearcontracting 4/9 5/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of AVXL's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

D Q2 2022 earnings call 2022-05-10

1 more research questions answered NO

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAMC · Altisource Asset ManagemAAON · AAON, Inc.AASZF · Atlantic Sapphire ASAAAT · American Assets Trust, IABCD · Cambium Learning Group'sABCO · The Advisory Board

AVX   All “A” companies    AVXS

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.